Strides Pharma Science Ltd
NSE:STAR
Strides Pharma Science Ltd
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Strides Pharma Science Ltd. engages in the development, manufacture and distribution of Internet Protocol-led generics and bio-pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The company went IPO on 2000-02-03. The firm is focused on development and manufacture of IP-led niche and pharmaceutical products. The company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The firm manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as, liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. The company has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). The company is also engaged in manufacturing soft gelatin capsules. The company develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
Profitability Focus: Strides delivered strong profitability, with gross margins at 59.8% and EBITDA margin at 19.8%, aided by business mix and cost control.
Revenue Growth: Revenue grew 3.6% year-on-year, with ex-U.S. markets driving 20% growth and now contributing 47% of total revenue.
U.S. Market Performance: U.S. revenues remained flat at $70 million, impacted by delayed flu season, increased competition, and product discontinuations.
Ex-U.S. Momentum: Other Regulated Markets (ORM) revenue broke past previous trends, reaching nearly $48 million with 21% growth, and Growth Markets delivered 19% growth.
Debt Reduction: Net debt reduced by INR 169 crores on a constant currency basis, with leverage (debt/EBITDA) improving to 1.59x.
Raised Expectations: Management reiterated medium-term ambitions: U.S. business to reach $400 million and ex-U.S. to mirror U.S. size by FY '28.
Operational Strength: Record reported PAT (profit after tax) of INR 208 crores; operational PAT up 39% YoY; cash-to-cash cycle stable at 124 days.
Leadership Additions: New CEO for North America and EVP of HR appointed, strengthening management for next phase of growth.
